Feline Fibrosarcoma (Non-Injection-Site)

Feline fibrosarcoma (non-injection-site) refers to malignant mesenchymal tumors arising from fibroblasts or related connective tissue cells that develop spontaneously at locations unrelated to prior vaccination or injection. Unlike the well-recognized feline injection-site sarcoma (FISS), non-injection-site fibrosarcomas tend to occur on the head, oral cavity, extremities, or trunk without a clear association with inflammatory stimuli from injections. These tumors are locally aggressive, capable of deep tissue invasion, and carry a significant risk of metastasis, making early diagnosis and intervention critical. They represent a less common but clinically important form of soft tissue sarcoma in domestic cats.

The precise etiology of non-injection-site feline fibrosarcoma is multifactorial and not fully elucidated. Unlike injection-site sarcomas—where chronic inflammation driven by adjuvants or tissue irritation is a recognized initiating event—spontaneous fibrosarcomas arise without a known inflammatory trigger.

Genetic and molecular factors: Mutations in tumor suppressor genes, particularly p53, have been identified in feline soft tissue sarcomas, allowing unregulated fibroblast proliferation. Dysregulation of cell cycle checkpoints and aberrant growth factor signaling (including platelet-derived growth factor receptor, PDGFR) contribute to neoplastic transformation and tumor progression.

Viral association: In young cats (typically under 4 years of age), feline sarcoma virus (FeSV)—a replication-defective retrovirus derived from recombination between feline leukemia virus (FeLV) and cellular proto-oncogenes—can cause multicentric fibrosarcomas. FeSV carries transduced oncogenes (such as v-fes, v-fms, or others) that constitutively activate growth-promoting signaling cascades. FeLV co-infection facilitates FeSV replication.

Spontaneous transformation: In older cats, sarcomas arise without viral involvement, likely through the accumulation of somatic mutations, chromosomal instability, and epigenetic alterations over time. Chronic UV radiation exposure (for tumors on sparsely haired areas) and unknown environmental carcinogens may play permissive roles.

Pathological mechanism: Malignant fibroblasts produce abundant abnormal collagen and extracellular matrix, forming a firm, infiltrative mass. These tumors grow by direct extension along fascial planes, making complete surgical margins difficult to achieve. Metastasis occurs hematogenously, with the lungs being the most common distant site, followed by regional lymph nodes.

Physical examination: A thorough physical examination identifies the location, size, texture, and adherence of the mass, and assesses regional lymph node enlargement.

Fine-needle aspiration cytology (FNA): FNA is a minimally invasive first step, though fibrosarcomas frequently exfoliate poorly (low cellularity), making cytological diagnosis inconclusive in many cases. It can nonetheless help rule out other tumor types.

Incisional or excisional biopsy with histopathology: Definitive diagnosis requires histological evaluation of tissue. Biopsy reveals interlacing bundles of spindle-shaped cells with pleomorphism, mitotic figures, and collagen production. Immunohistochemistry (e.g., vimentin positivity, variable smooth muscle actin) can help confirm fibroblastic origin and differentiate from other spindle cell tumors (e.g., nerve sheath tumors, leiomyosarcoma).

Staging and imaging:

• ·Thoracic radiography (three views): Essential to detect pulmonary metastases before treatment planning
• ·Regional lymph node assessment: Palpation, FNA, or biopsy of draining lymph nodes
• ·CT scan: Preferred for surgical planning; provides detailed information about tumor margins, vascular involvement, bone invasion, and relationship to adjacent structures, particularly for oral or limb tumors
• ·Abdominal ultrasound: Evaluates for abdominal lymph node involvement or organ metastasis

Laboratory evaluation: While no pathognomonic laboratory findings exist for fibrosarcoma, a complete blood panel assists in staging and treatment planning:

• ·CBC: May reveal mild non-regenerative (normocytic, normochromic) anemia (low HCT/PCV) consistent with anemia of chronic disease; thrombocytosis (elevated PLT) may occur as a paraneoplastic phenomenon; leukocytosis (elevated WBC) if secondary infection or tumor necrosis is present
• ·Serum biochemistry: Low albumin (ALB) reflects cancer-associated cachexia or protein loss; elevated globulins (GLOB) may indicate chronic inflammation; ALT elevation possible if hepatic metastasis or concurrent liver disease is present; BUN and CREA evaluated to confirm renal function is adequate for chemotherapy or NSAID use
• ·FeLV/FIV testing: Recommended in young cats with multicentric or aggressive sarcomas to assess retroviral involvement

Surgery: Wide surgical excision remains the cornerstone of treatment. Achieving histologically clean margins (recommended ≥2–3 cm lateral margins and one uninvolved fascial plane deep margin) is critical for local tumor control but is often difficult given the infiltrative nature of these tumors. For distal limb tumors, amputation frequently provides the best chance of complete excision and is well-tolerated by cats. Debulking alone (incomplete excision) is associated with rapid local recurrence.

Radiation therapy (RT): RT is employed as an adjuvant following surgery when margins are incomplete or narrow, or when anatomical constraints (e.g., oral cavity, trunk) preclude wide resection. Both definitive (curative-intent, higher dose per fraction) and palliative fractionation protocols are used. Radiation combined with surgery improves local control compared to surgery alone.

Chemotherapy: The role of chemotherapy in feline non-injection-site fibrosarcoma is less defined than in injection-site sarcomas, but similar protocols are often extrapolated:

• ·Doxorubicin (single agent or in combination) is the most commonly used cytotoxic agent; typical feline dosing is 1 mg/kg IV every 3 weeks
• ·Cyclophosphamide or ifosfamide may be used in combination protocols
• ·Carboplatin has shown activity in some feline sarcoma cases
• ·Chemotherapy is most often employed in the adjuvant setting after surgery, in cases with incomplete margins, lymph node involvement, or high-grade histology, or for metastatic disease

Targeted and emerging therapies: Toceranib phosphate (Palladia), a receptor tyrosine kinase inhibitor, has been explored in feline sarcomas given the expression of PDGFR and other targets, though evidence specific to non-injection-site fibrosarcoma remains limited.

Palliative and supportive care:

• ·NSAIDs (e.g., meloxicam) for pain management and possible mild anti-tumor effects, with renal monitoring
• ·Opioid analgesia (e.g., buprenorphine) for moderate-to-severe pain
• ·Appetite stimulants (mirtazapine) and high-calorie nutritional support to manage cachexia
• ·Wound management for ulcerated tumors
• ·Antibiotic therapy if secondary bacterial infection of necrotic tumor tissue is present

The prognosis for feline non-injection-site fibrosarcoma is generally guarded to poor, influenced heavily by tumor location, histological grade, completeness of surgical excision, and presence of metastatic disease at diagnosis.

Local recurrence: Because these tumors are infiltrative and complete surgical excision is frequently not achieved, local recurrence rates are high. Recurrence often occurs within weeks to a few months of surgery when margins are incomplete.

Metastatic rate: Metastasis is reported in a substantial proportion of feline soft tissue sarcomas; pulmonary metastasis is most common and may be present at diagnosis in approximately 20–25% of cases, with higher rates detected at necropsy.

Survival times: Specific long-term survival statistics for non-injection-site fibrosarcomas as a distinct entity are limited in the veterinary literature. By extrapolation from feline soft tissue sarcoma data:

• ·Cats treated with surgery alone and incomplete margins typically survive median 3–6 months before local recurrence necessitates further intervention
• ·Cats with wide, complete excision and no detectable metastasis may achieve median survival times of 12–24 months or longer
• ·Multimodal therapy (surgery + radiation ± chemotherapy) generally confers the best outcomes

FeSV-associated fibrosarcoma (young cats): These cases carry a particularly grave prognosis due to multifocal tumor development, rapid progression, and associated FeLV immunosuppression; survival is often measured in weeks to a few months.

Histological grade is a key prognostic indicator: high-grade tumors (high mitotic index, extensive necrosis, marked pleomorphism) have significantly shorter survival and higher metastatic rates than low-grade tumors.

Data on long-term prognosis specific to this tumor type is limited in current veterinary literature; no peer-reviewed survival statistics exclusively for non-injection-site feline fibrosarcoma were identified in the references cited above, and the figures above represent extrapolations from broader soft tissue sarcoma literature.

FeLV vaccination and testing: Since FeSV-associated fibrosarcoma requires FeLV co-infection for viral replication, maintaining cats on a current FeLV vaccination schedule and testing new cats before introduction into a multi-cat household reduces the risk of the virally induced form, particularly in young cats with outdoor access.

FeLV risk reduction: Keeping cats indoors, preventing contact with FeLV-positive cats, and testing all cats in multi-cat environments are important preventive strategies.

Early detection: Routine veterinary wellness examinations (at least annually, semi-annually in cats over 7 years) facilitate early detection of new masses. Owners should be instructed to report any new subcutaneous lump, oral mass, or unexplained facial swelling promptly.

No specific dietary or environmental prevention has been established for spontaneous fibrosarcomas, reflecting the likely polygenic and multifactorial nature of their development.

Prompt biopsy of new soft tissue masses: Early histological diagnosis allows intervention before extensive local invasion or metastasis occurs, improving the chances of complete excision and better outcomes.

General health and immune support: Maintaining optimal body condition, reducing environmental stressors, and keeping concurrent diseases well-managed supports overall immune function, though a direct preventive effect on fibrosarcoma development has not been demonstrated.